Literature DB >> 28903607

Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis.

Simone Giuliano1, Maurizio Guastalegname1, Alessandro Russo1, Marco Falcone1, Veronica Ravasio2, Marco Rizzi2, Matteo Bassetti3, Pierluigi Viale4, Maria Bruna Pasticci5, Emanuele Durante-Mangoni6, Mario Venditti1.   

Abstract

INTRODUCTION: Candida Endocarditis (CE) is a deadly disease. It is of paramount importance to assess risk factors for acquisition of both Candida native (NVE) and prosthetic (PVE) valve endocarditis and relate clinical features and treatment strategies with the outcome of the disease. Areas covered: We searched the literature using the Pubmed database. Cases of CE from the Italian Study on Endocarditis (SEI) were also included. Overall, 140 cases of CE were analyzed. Patients with a history of abdominal surgery and antibiotic exposure had higher probability of developing NVE than PVE. In the PVE group, time to onset of CE was significantly lower for biological prosthesis compared to mechanical prosthesis. In the whole population, greater age and longer time to diagnosis were associated with increased likelihood of death. Patients with effective anti-biofilm treatment, patients who underwent cardiac surgery and patients who were administered chronic suppressive antifungal treatment showed increased survival. For PVE, moderate active anti-biofilm and highly active anti-biofilm treatment were associated with lower mortality. Expert commentary: Both NVE and PVE could be considered biofilm-related diseases, pathogenetically characterized by Candida intestinal translocation and initial transient candidemia. Cardiac surgery, EAB treatment and chronic suppressive therapy might be crucial in increasing patient survival.

Entities:  

Keywords:  Candida; amphotericin; biofilm; candidemia; echinocandin; endocarditis; intestinal translocation; triazole

Mesh:

Substances:

Year:  2017        PMID: 28903607     DOI: 10.1080/14787210.2017.1372749

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

1.  Contemporary comparison of infective endocarditis caused by Candida albicans and Candida parapsilosis: a cohort study.

Authors:  Adrián Jerónimo; Carmen Olmos; Isidre Vilacosta; Carmen Sáez; Javier López; Marta Sanz; Gonzalo Cabezón; Javier B Pérez-Serrano; Pablo Zulet; J Alberto San Román
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-14       Impact factor: 3.267

2.  Study on the Relationship between AAD and Clinical Features in Emergency Ward Patients and the Application Effect of Probiotics.

Authors:  Wenjuan Qiu; Fangfang Bai
Journal:  Contrast Media Mol Imaging       Date:  2022-07-11       Impact factor: 3.009

3.  Candida parapsilosis endocarditis. Report of cases and review of the literature.

Authors:  Petros Ioannou; Maria Volosyraki; Vasiliki Mavrikaki; Ioanna Papakitsou; Anna Mathioudaki; George Samonis; Diamantis P Kofteridis
Journal:  Germs       Date:  2020-09-01

4.  Huge Candida albicans normal native tricuspid valve endocarditis.

Authors:  Massimiliano Guerriero; Francesco Colasurdo; Anna Maria Pollio
Journal:  Autops Case Rep       Date:  2018-04-18

Review 5.  Candida Endocarditis: A Review of the Pathogenesis, Morphology, Risk Factors, and Management of an Emerging and Serious Condition.

Authors:  Sahil Mamtani; Nawar Muneer Aljanabi; Robins P Gupta Rauniyar; Ashu Acharya; Bilal Haider Malik
Journal:  Cureus       Date:  2020-01-18

6.  Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation.

Authors:  Brad J Girod; Kip E Guja; Guido Davidzon; Francis Chan; Evan Zucker; Benjamin L Franc; Farshad Moradi; Andrei Iagaru; Carina Mari Aparici
Journal:  Radiol Case Rep       Date:  2019-11-19

7.  Not "Much Room" in the Heart: A Rare Case of a Massive Intracardiac Candida Mass.

Authors:  Ali Haider Jafry; Sardar Hassan Ijaz; Murtaza Mazhar; Areeba Shahnawaz; Ali Yousif
Journal:  Case Rep Infect Dis       Date:  2021-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.